Befejeződött3. fázis
Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma
Key facts
- Where
- Bordeaux, Nice és Paris, FranciaországSee the 3 sites
- Phase
- 3. fázis
Where in Franciaország
- Centre Rétine GallienBordeaux, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de NiceNice, FranciaországNo longer taking part
- Quinze-Vingts National Ophthalmology HospitalParis, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire De Nice
- Trial code
- EU 2024-513746-11-00
- Record updated
- 2024. december 19.
- Original description
Compare neovascular glaucoma rate 5 years after proton therapy, in patients large with choroid melanoma, between a group of patients treated preventively by intravitreal anti-VEGF versus a second group of patients receiving a false injection.Read full original descriptionShow less
Compare neovascular glaucoma rate 5 years after proton therapy, in patients large with choroid melanoma, between a group of patients treated preventively by intravitreal anti-VEGF versus a second group of patients receiving a false injection.
Inclusion: Age ≥ 18 years; Choroid melanoma more than 7 mm thick and / or over basal diameter of 15mm treated by proton therapy.
Exclusion: Known hypersensitivity to aflibercept (anti-VEGF selected); Iris melanoma; Melanoma immediately metastatic; Pregnant or breastfeeding women.